TRDA ▲ +3.5% - Entrada Therapeutics, Inc.
$TRDA - Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14-OCT-2026 07:00 AM ET
Share this post
More filings for $TRDA
TRDA ▲ +3.5% - Entrada Therapeutics, Inc.Oct 14, 2026TRDA - Entrada Therapeutics, Inc. - SEC Filing Update (10-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 10, 2026TRDA ▲ +1.4% - Entrada Therapeutics, Inc.Sep 10, 2026TRDA ▲ +2.8% - Entrada Therapeutics, Inc.Sep 2, 2026TRDA - Entrada Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $TRDA filing history →💬 Comments
Loading comments…
Leave a comment